Segment and Geographic Information

9 Months Ended

Sep. 30, 2015

Segment Reporting [Abstract]

Segment and Geographic Information

Segment and Geographic Information

The Company manages its business and operations as one segment and is focused on advancing the treatment of acute and intensive care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. Revenues reported to date are derived primarily from the sales of Angiomax in the United States.

The geographic segment information provided below is classified based on the major geographic regions in which the Company operates.

	Three Months Ended September 30,								Nine Months Ended September 30,
	2015				2014				2015			2014
	(in thousands)								(in thousands)
Net revenue:
United States	$	68,746	94.6	%	$	164,935	95.6	%	$	274,771	94.9%	$	505,312	94.7%
Europe	3,495		4.8	%	6,651		3.9	%	13,132		4.5%	25,160		4.7%
Rest of world	437		0.6	%	815		0.5	%	1,763		0.6%	2,938		0.6%
Total net revenue	$	72,678	100.0	%	$	172,401	100.0	%	$	289,666	100.0%	$	533,410	100.0%

	September 30, 2015				December 31, 2014
	(in thousands)
Long-lived assets:
United States	$	1,377,666	99.4	%	$	1,218,370	99.3	%
Europe	8,136		0.6	%	8,899		0.7	%
Rest of world	—		—	%	16		—	%
Total long-lived assets	$	1,385,802	100.0	%	$	1,227,285	100.0	%